Literature DB >> 10574905

Health economics of heart failure.

M Malek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10574905      PMCID： PMC1766521          DOI： 10.1136/hrt.82.2008.iv11

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  6 in total

Review 1.  The pharmacoeconomics of ACE inhibitors in chronic heart failure.

Authors:  J McMurray; A Davie
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

2.  Cost effectiveness of carvedilol for heart failure.

Authors:  T E Delea; M Vera-Llonch; R E Richner; M B Fowler; G Oster
Journal:  Am J Cardiol       Date:  1999-03-15       Impact factor: 2.778

3.  Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany.

Authors:  P K Schädlich; B Paschen; J G Brecht
Journal:  Pharmacoeconomics       Date:  1998-01       Impact factor: 4.981

4.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

5.  A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study.

Authors:  P Levy; P Lechat; A Leizorovicz; E Levy
Journal:  Cardiovasc Drugs Ther       Date:  1998-07       Impact factor: 3.727

Review 6.  Cost-effectiveness analysis in heart disease, Part II: Preventive therapies.

Authors:  J Kupersmith; M Holmes-Rovner; A Hogan; D Rovner; J Gardiner
Journal:  Prog Cardiovasc Dis       Date:  1995 Jan-Feb       Impact factor: 8.194
  6 in total
  6 in total

Review 1.  Determinants of heart failure self-care: a systematic literature review.

Authors:  R Oosterom-Calo; A J van Ballegooijen; C B Terwee; S J te Velde; I A Brouwer; T Jaarsma; J Brug
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  Lifetime costs of medical care after heart failure diagnosis.

Authors:  Shannon M Dunlay; Nilay D Shah; Qian Shi; Bruce Morlan; Holly VanHouten; Kirsten Hall Long; Véronique L Roger
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-12-07

3.  Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.

Authors:  M Ekman; N Zethraeus; B Jönsson
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Economic burden of heart failure in the elderly.

Authors:  Lawrence Liao; Larry A Allen; David J Whellan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure.

Authors:  Hiroyuki Nakayama; Xiongwen Chen; Christopher P Baines; Raisa Klevitsky; Xiaoying Zhang; Hongyu Zhang; Naser Jaleel; Balvin H L Chua; Timothy E Hewett; Jeffrey Robbins; Steven R Houser; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  Designing Novel Therapies to Mend Broken Hearts: ATF6 and Cardiac Proteostasis.

Authors:  Erik A Blackwood; Alina S Bilal; Winston T Stauffer; Adrian Arrieta; Christopher C Glembotski
Journal:  Cells       Date:  2020-03-03       Impact factor: 6.600
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.